Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1 by Burbulla, L. F. et al.
OPEN
Mitochondrial proteolytic stress induced by loss
of mortalin function is rescued by Parkin and PINK1
LF Burbulla1,2,12, JC Fitzgerald1,2,12, K Stegen1,2,3, J Westermeier1,2,3, A-K Thost4, H Kato5, D Mokranjac6, J Sauerwald1,2, LM Martins7,
D Woitalla8, D Rapaport5, O Riess9, T Proikas-Cezanne4, TM Rasse*,10 and R Krüger*,1,2,11
The mitochondrial chaperone mortalin was implicated in Parkinson’s disease (PD) because of its reduced levels in the brains of
PD patients and disease-associated rare genetic variants that failed to rescue impaired mitochondrial integrity in cellular
knockdown models. To uncover the molecular mechanisms underlying mortalin-related neurodegeneration, we dissected the
cellular surveillance mechanisms related to mitochondrial quality control, defined the effects of reduced mortalin function at the
molecular and cellular levels and investigated the functional interaction of mortalin with Parkin and PINK1, two PD-related
proteins involved in mitochondrial homeostasis. We found that reduced mortalin function leads to: (1) activation of the
mitochondrial unfolded protein response (UPR(mt)), (2) increased susceptibility towards intramitochondrial proteolytic stress,
(3) increased autophagic degradation of fragmented mitochondria and (4) reduced mitochondrial mass in human cells in vitro
and ex vivo. These alterations caused increased vulnerability toward apoptotic cell death. Proteotoxic perturbations induced by
either partial loss of mortalin or chemical induction were rescued by complementation with native mortalin, but not disease-
associated mortalin variants, and were independent of the integrity of autophagic pathways. However, Parkin and PINK1 rescued
loss of mortalin phenotypes via increased lysosomal-mediated mitochondrial clearance and required intact autophagic
machinery. Our results on loss of mortalin function reveal a direct link between impaired mitochondrial proteostasis, UPR(mt)
and PD and show that effective removal of dysfunctional mitochondria via either genetic (PINK1 and Parkin overexpression) or
pharmacological intervention (rapamycin) may compensate mitochondrial phenotypes.
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Although 18 genetic disease loci and several environmental
factors have been identified (reviewed in Sharma et al.1) that
contribute to Parkinson’s disease (PD), the exact pathogenic
mechanisms remain elusive.2 Neuronal function critically
relies on intact mitochondrial homeostasis. Impaired mito-
chondrial function and dynamics alter neuronal bioenergetics,
an underlying factor in aging and a number of neurode-
generative diseases, leading to programmed cell death.3,4
Several PD-associated genes such as PINK1, Parkin or
DJ-1 encode proteins that are closely linked to mitochondrial
quality control, thus providing an important molecular link
between mitochondrial homeostasis and neurodegeneration
observed in PD. Disease-related mutations in these genes
cause loss of protein function and contribute to impaired
mitochondrial integrity as revealed by the loss of mitochondrial
membrane potential (MMP), disrupted mitochondrial morphology
and reduced activity of complex I of the electron transport
chain.5–7
Unbiased biochemical approaches identified the mitochon-
drial stress response protein mortalin (also known as glucose
regulated protein 75 (GRP75) or mitochondrial heat shock
protein 70 (mtHsp70)) as an interactor of Parkin, PINK1 and
DJ-1.8–11 Mortalin is a member of the Hsp70 family and was
identified as a molecular chaperone within the mitochondrial
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Centre for Integrative Neuroscience, University of Tübingen, Tübingen, Germany
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matrix.8,12–14 As the only ATPase component of the
mitochondrial import complex, mortalin is essential for the
effective import and folding of nuclear-encoded mitochondrial
matrix proteins as well as for the proper degradation of altered
or impaired mitochondrial proteins.15,16 Mortalin is a key
player in mitochondrial stress response, aging and pro-
grammed cell death.17–19 Overexpression of mortalin extends
lifespan in human cells and the nematode C. elegans,
indicating a protective function in vitro and in vivo.11,20,21 In
contrast, partial loss of mortalin results in alterations in
mitochondrial morphology, impaired MMP and increased
cellular levels of reactive oxygen species (ROS).11 Analysis
of three PD-associated variants in the mortalin gene revealed
a loss of protective mortalin function in human cells.11
Notably, mortalin was linked to neurodegeneration in PD
based on substantially reduced levels of the protein in brain
samples of patients.19,22 It was further observed that the
reduction in the levels of mortalin in patients correlated with
the disease stage.22 RNAi-mediated knockdown of mortalin in
Drosophila recapitulates defects observed in other inverte-
brate PD models, reducing cellular ATP levels and inducing
defects in body posture and locomotion.23 Importantly, loss of
synaptic mitochondria, mediated by mitophagy, was observed
early in disease progression23 and also preceded behavioral
impairments and changes in synaptic morphology in other
PD-associated Drosophila models.24,25
In order to investigate how loss of mortalin function relates to
neurodegeneration in PD and influences mechanisms related
to molecular and organellar quality control, we studied both
in vitro and ex vivo cellular models. Our results reveal a primary
defect in intramitochondrial protein quality control because of
loss of mortalin associated with an increased mitochondrial
unfolded protein response (UPR(mt)) and increased suscept-
ibility of cells toward intramitochondrial proteolytic stress. The
proteotoxic perturbations caused by loss of mortalin or
chemical induction were rescued by complementation with
wild-type (wt) mortalin, but not PD-associated mortalin variants,
and were independent of downstream autophagic clearance
machinery. Importantly, Parkin and PINK1 rescued loss of
mortalin-associated mitochondrial fragmentation and apoptotic
cell death via an activation of autophagic clearance of
mitochondria. Importantly, a successful rescue was dependent
on intact lysosomal degradation pathways.
Collectively, we provide first insights into the role of the
intramitochondrial protein quality control in PD and integrate
mortalin defects into molecular pathways related to PINK1/
Parkin-mediated organellar homeostasis in PD pathogenesis.
Results
Loss of mortalin increases intramitochondrial proteolytic
stress. As a mitochondrial chaperone in the mitochon-
drial matrix, mortalin is critically required for the proper
import and folding of nuclear-encoded matrix proteins.17 We
hypothesized that PD-associated loss of mortalin function
initiates impaired mitochondrial protein homeostasis. We first
sought to measure the ratio of nuclear-encoded ATP5A to
the mitochondrially encoded MTCO1 to assess potential
mitonuclear imbalance. Mitonuclear imbalance was recently
reported to precede activation of UPR(mt), together
comprising a stress-signaling pathway conserved across
many species.26 We found reduced mitochondrially encoded
MTCO1 protein levels in mortalin knockdown cells compared
with controls, whereas the level of nuclear-encoded ATP5A
remained the same (Figure 1a). To further investigate the
relevance of loss of mortalin to mitochondrial quality control,
we measured the levels of the mitochondrial chaperone
Hsp60 as a marker for the UPR(mt) as this protein is
upregulated in conditions of intramitochondrial proteolytic
stress (reviewed in Broadley and Hartl27). To assess the
intramitochondrial stress response upon loss of mortalin
function, we analyzed the Hsp60 protein levels after mortalin
knockdown in human neuroblastoma (SH-SY5Y) cells and in
human fibroblasts from a heterozygous carrier of the
PD-associated A476T mortalin variant (hereafter named
A476T-fibroblasts). To validate the efficacy of mortalin
knockdown in human neuroblastoma cells, mortalin levels
were quantified. Western blot analysis revealed B70%
reduction in mortalin protein (Supplementary Figure S1a).
Because the abundance of Hsp60 may depend on the
mitochondrial mass, we normalized our results to a mitochon-
drial marker (Tom20). We observed increased levels of Hsp60
in SH-SY5Y cells with reduced mortalin levels (Figure 1b).
Similar alterations in Hsp60 levels were found in A476T-
fibroblasts compared with control fibroblasts that may reflect a
chronic activation of UPR(mt) in mutant cells (Figure 1c). Our
results on mitonuclear imbalance and upregulation of the
stress protein Hsp60 suggest that loss of mortalin function
induces a mitochondrial stress response arising within the
mitochondria. We hypothesize that the mitochondrial stress,
mitonuclear imbalance and UPR(mt) activation in cells lacking
functional mortalin would arise as a result of proteolytic stress.
Therefore, we investigated whether mortalin knockdown
causes an accumulation of aggregated or insoluble proteins
within mitochondria by silver staining. As a result, no
differences in the levels of SDS-soluble proteins within the
mitochondria of mortalin knockdown or control cells were
observed, but a significant increase in the amount of insoluble
aggregates from the same mitochondrial sample was
observed (Figure 1d). This indicates an increase in aggregated
proteins within mitochondria upon loss of mortalin function that
might arise from the significant amount of unfolded or
misfolded proteins that could not be degraded efficiently.
Activation of the UPR(mt) might sensitize or protectively
precondition cells toward a second insult that causes further
intramitochondrial stress. To differentiate these two possibi-
lities, we induced intramitochondrial stress genetically
by expressing the mitochondrial matrix protein ornithine
transcarbamylase (OTC) or its truncated variant (dOTC)
harboring a FLAG tag in SH-SY5Y cells. The accumulation of
the truncated variant in an unfolded state within the
mitochondrial matrix has been previously shown to elicit an
intramitochondrial proteolytic stress response paralleled by
Hsp60 upregulation.28,29 Both native OTC and dOTC were
correctly targeted to mitochondria upon overexpression
(Figure 2a). As expected, overexpression of the truncated
dOTC variant led to a more punctate pattern in both
conditions, control as well as mortalin knockdown. Interest-
ingly, we also observed a more punctate pattern after
overexpression of native OTC in mortalin knockdown cells
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that was not obvious in controls cells. Therefore, we analyzed
the area of mitochondria (Tom20 signal) that colocalized with
the area covered by OTC signal as a readout for proper
intraorganellar distribution of the protein. The mitochondrial
area covered by the OTC signal was significantly reduced in
mortalin knockdown cells (Figure 2b). This may indicate an
increased tendency of native OTC to aggregate in a mortalin
knockdown background and argues in favor of an imbalanced
protein folding capacity within the matrix.
Intramitochondrial proteolytic stress due to mortalin
knockdown affects mitochondrial integrity similar to
dOTC expression. Impaired intramitochondrial protein
quality control affects mitochondrial morphology and
dynamics.30,31 We next extended our previous findings on
mitochondrial fragmentation in A476T-fibroblasts11 to a
human neuronal cell line and confirmed the characteristic
fragmentation of the mitochondrial network in response to
mortalin knockdown as assessed by aspect ratio, form factor
and mitochondrial area per single mitochondrion (mitochon-
drial size) (Figure 3a). In contrast to wt mortalin, the PD-
associated mortalin variants were not able to rescue the
disturbed mitochondrial network caused by reduced mortalin
function. Next, we used dOTC as a tool to genetically induce
intramitochondrial proteolytic stress and then investigated
mitochondrial integrity in SH-SY5Y cells with or without
mortalin knockdown. Expression of dOTC in SH-SY5Y cells
treated with control siRNA resulted in the fragmentation of
the mitochondrial network as described previously for
nonneuronal human cells28 (Figure 3b). The expression of
native OTC in control cells did not affect mitochondrial
integrity. Interestingly, overexpression of dOTC in control
siRNA-treated cells recapitulated the mitochondrial fragmen-
tation seen in SH-SY5Y cells with reduced mortalin levels.
Moreover, expression of dOTC in the mortalin knockdown
background further exacerbated the mitochondrial fragmen-
tation phenotype compared with native OTC. The effect of
dOTC on mitochondrial integrity is similar in both control and
mortalin knockdown cells with no significant synergistic effect
Figure 1 Loss of mortalin evokes a mitochondrial stress response via Hsp60 in
human cells. (a, left panel) Western blot analysis of protein levels of the nuclear-
encoded complex V a-subunit (ATP5A) and the mitochondrially encoded complex
IV subunit MTCO1 in SH-SY5Y cells transfected with mortalin miRNA and a
nontargeting control miRNA (Ctrl). Mitochondrially encoded MTCO1 levels are
reduced compared with control, whereas there are no changes in ATP5A and the
loading control TOM20. (a, right panel) Quantification by densitometry and
calculation of the ATP5A/MTCO1 ratio showed a significantly higher ratio in mortalin
knockdown cells indicating mitonuclear imbalance, n¼ 3. (b, left panel)
Immunoblotting analysis of Hsp60 levels in SH-SY5Y cells. A representative
immunoblot shows increased Hsp60 protein levels upon mortalin knockdown.
(b, right panel) Densitometric analysis of average Hsp60 levels, normalized to
Tom20 levels, n¼ 3. (c, left panel) Immunoblotting analysis of Hsp60 levels in
human fibroblasts from a carrier of a loss of mortalin variant compared with
fibroblasts from a healthy sibling control. A representative immunoblot shows
increased Hsp60 protein levels in the A476T fibroblasts. It is noteworthy that no
reduction of the overall levels of mortalin can be expected as fibroblasts from a
human carrier of the A476T mutation express both the mutant and the wild-type
allele. (c, right panel) Densitometric analysis of average Hsp60 levels normalized to
b-actin loading control and expressed as a percentage of control fibroblasts, n¼ 3.
(d) Silver staining of soluble and insoluble mitochondrial extracts from SH-SY5Y
cells transfected with mortalin miRNA and a nontargeting control miRNA (Ctrl).
A total of 1 mg of total crude mitochondrial extracts were split and incubated in equal
volumes of buffer containing 2% SDS (soluble) and 1% NP40 (insoluble). Insoluble
proteins from mitochondria were isolated from the 1% NP40 fraction by high-speed
centrifugation. Equal volumes of the soluble SDS fraction or the insoluble protein
pellet were resolved on NuPAGE 4–12% gradient gels and subsequent silver
staining. Whereas the soluble fraction shows a similar amount of total protein for
both miRNAs, the insoluble fraction exhibits an enrichment in 1% NP40-insoluble
protein in the mortalin knockdown condition compared with the control
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in the latter condition. This may indicate that the altered
mitochondrial morphology readout reaches saturation,
although we cannot rule out the possibility that less dOTC
is imported into the mitochondria in the mortalin knockdown
situation or that the level of proteolytic stress is saturated
under two equally toxic conditions.
As fragmentation precedes the degradation of dysfunc-
tional mitochondria, we investigated an additional down-
stream readout and measured whether the observed
increased mitochondrial fragmentation translates into
changes of mitochondrial mass. Knockdown of mortalin in
SH-SY5Y cells reduced the abundance of the outer
Figure 2 Intramitochondrial proteolytic stress phenocopies the reduced viability seen in loss of mortalin function models. (a) Intramitochondrial proteolytic stress in
SH-SY5Y cells (n¼ 73) was genetically induced by overexpression of a truncated form of the matrix protein OTC referred to as dOTC. Immunocytochemical studies in fixed
cells reveal both OTC and dOTC protein (GFP-green) located within mitochondrial structures shown as Tom20 signal (far red). siRNA transfection was confirmed by
fluorescence of the Alexa555 siRNA tag (red). The expressed OTC protein is equally distributed in control cells, but is punctate in mortalin siRNA-treated cells. Quality control
experiments to ensure equal expression of OTC and dOTC were performed (data not shown). Scale bars indicate 10 mm. (b) Subsequent ImageJ analysis was done from
immunocytochemical studies in Figure 1a. The total area of mitochondria (Tom20 signal) colocalizing with OTC was less in the mortalin knockdown condition compared with
the control condition
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Figure 3 (Continued)
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Figure 3 Proteolytic stress alters mitochondrial morphology in loss of mortalin function models. (a) Fluorescence microscopy in fixed cells (n¼ 220 cells) was used to
analyze mitochondrial morphology in mortalin and control siRNA-treated SH-SY5Y with or without overexpressed wt mortalin or mortalin variants. Successful siRNA
transfection was confirmed by fluorescence of the Alexa555 tag of the siRNA (red). Mitochondria were visualized by Tom20 antibody (far red) and Hoechst 33342-stained
nuclei (blue). Mortalin siRNA-treated cells have a smaller mitochondrial form factor, aspect ratio and mitochondrial size (area per mitochondrion). The reintroduction of wt
mortalin but not the variants rescued this mitochondrial fragmentation phenotype. Ctrl, control; EV, empty vector. Scale bar indicates 10 mm. (b) Immunocytochemical studies
in fixed SH-SY5Y cells (n¼ 138) treated with control siRNA or mortalin siRNA were additionally transfected with OTC or dOTC protein, and mitochondrial morphology
analyzed. The expression of the dOTC protein leads to a fragmentation phenotype in control siRNA-treated cells. The aspect ratio as well as the form factor was decreased
compared with control cells expressing the physiological OTC protein. The expression of OTC in a mortalin knockdown background phenocopied the control condition
expressing dOTC. Mortalin knockdown cells with transiently transfected dOTC lead to the most severe mitochondrial fragmentation phenotype. (c) The mitochondrial mass of
SH-SY5Y cells (n¼ 92) treated with mortalin siRNA or control siRNA (red) was analyzed by evaluating the total area of mitochondria (green) per cell via live cell imaging.
Nuclei were visualized by DAPI stain (blue). Knockdown of mortalin caused a significant reduction in mitochondrial mass. Scale bar indicates 10mm. (d) In human fibroblasts
(n¼ 82), a reduced mitochondrial mass (green) was calculated for cells from a carrier of the A476T mortalin variant compared with controls via live cell imaging technique.
Nuclei were visualized by DAPI stain (blue). Scale bar indicates 10 mm. (e) Induction of intramitochondrial proteolytic stress by expression of dOTC protein within siRNA
control-treated cells leads to reduced mitochondrial mass measured by immunocytochemical studies in fixed cells and subsequent ImageJ analysis. Expression of OTC protein
in mortalin knockdown cells caused a similar reduction of mitochondrial mass seen in control cells expressing dOTC protein. Expression of dOTC in mortalin siRNA-treated
caused the most severe loss of mitochondrial structures. N¼ 138 cells
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mitochondrial membrane protein Tom20 (Supplementary
Figure S1b) and the total area of mitochondria per cell
(Figure 3c), suggesting a reduction in mitochondrial mass.
This was supported by live cell imaging analyses in A476T-
fibroblasts stained with Mitotracker green, a mitochondrial
dye not dependent on MMP (Figure 3d). In line with
intramitochondrial proteolytic stress modulating mitochondrial
dynamics, the expression of dOTC within control siRNA-
treated cells led to a significant reduction of mitochondrial
mass (Figure 3e). Again, combining mortalin knockdown and
expression of dOTC resulted in a more severe reduction
of mitochondrial mass. This indicates synergistic intramito-
chondrial proteolytic stress conditions in terms of overall
mitochondrial mass.
Knockdown of mortalin elevates autophagic activity and
the specific degradation of mitochondria. Because of
compensatory induction of organellar quality control mechan-
isms, intramitochondrial proteolytic stress should promote
the specific degradation of dysfunctional mitochondria
through autophagic clearance. To address this possibility,
we employed several measures to assess autophagy
by quantitative fluorescence microscopy techniques:
(1) assessment of overexpressed GFP-LC3 puncta by
confocal microscopy; (2) endogenous WIPI-2 puncta forma-
tion by confocal microscopy; (3) automated high-throughput
imaging and analysis of endogenous p62; and (4) colocaliza-
tion of lysosomes and mitochondria. Indeed, we found
that mortalin knockdown results in a significantly higher
level of autophagic activity and mitochondrial-lysosomal
colocalisation, a measure of mitophagy.
In detail, we used transiently overexpressed GFP-LC3 in
SH-SY5Y to assess the number of autophagosomes by
quantitative fluorescence microscopy.32 We found that the
number of GFP-LC3 puncta per cell significantly increased in
response to mortalin knockdown (Figure 4a), and this was
abolished by overexpressing wt mortalin, but only partially by
any of the PD-associated mortalin variants (Figure 4a).
An increased number of autophagosomes (GFP-LC3 puncta)
per cell can either be the result of an increased level in
autophagy initiation or of a block in later stages of autophagy
when autophagosomes contact the lysosomal compartment
for final cargo degradation (autophagic flux).33 Hence, we
monitored the autophagic flux by standard cotreatments with
the lysosomal inhibitor bafilomycin A1 (BafA1) that prevents
the fusion between autophagosomes and lysosomes. As
expected, the addition of BafA1 elevated the number of GFP-
LC3 puncta per cell under control conditions (Figure 4b). The
number of GFP-LC3 puncta per cell clearly increased upon
BafA1-treated mortalin knockdown when compared with both
untreated mortalin knockdown cells and control siRNA cells
treated with BafA1 (Figure 4b). This result strongly indicates
that the autophagic activity increases upon mortalin
knockdown.
For further autophagy assessments we employed
SH-SY5Y cells with inducible expression of miRNA targeting
mortalin (Figure 4c and Supplementary Figures S2–S4).
By analyzing endogenous LC3 lipidation, the conjugation
of LC3 (LC3-I) to phosphatidylethanolamine (LC3-II), we
confirmed proper autophagic activity in this cellular model
(Supplementary Figure S2). Next, we monitored the specific
localization of endogenous WIPI-2, a member of the WIPI
protein family34 that functions as an essential phosphotidyl-
inositol-3-phosphate (PtdIns(3)P) effector during autophagy
initiation.35 Upon autophagy initiation, WIPI-2 accumulates at
early and late autophagosomal membranes,36,37 and hence
autophagy initiation can also be assessed by quantitative
fluorescent puncta formation. In line with our results using
GFP-LC3, we found a significant increase of endogenous
WIPI-2 puncta when mortalin is knocked down (Figure 4c and
Supplementary Figure S3). Furthermore, using an automated
high-throughput imaging and analysis platform,37 we ana-
lyzed the specific targeting of endogenous p62 by autophagic
clearance and found an increase in p62 degradation in cells
lacking endogenous mortalin (Supplementary Figure S4). In
summary, our autophagy assessments strongly indicate that
mortalin negatively controls the process of autophagy and that
mortalin knockdown results in elevated autophagic activity.
As autophagy controls both the function and numbers of
cellular organelles including mitochondria, we addressed the
question of whether or not autophagy activation upon mortalin
knockdown would lead to an elevated level of specific
mitochondrial clearance called mitophagy (Figure 4d). For
this aim, we quantified the colocalization of mitochondria,
marked with Tom20 antibodies, with lysosomes, marked with
LAMP1 antibodies, as a measure of mitophagy.33 Indeed, we
found a higher degree of colocalization in cells treated with
mortalin siRNA compared with controls, indicating increased
autophagic clearance of dysfunctional mitochondria
(Figure 4d). This effect was abolished by wt mortalin
overexpression into the knockdown background but not by
mutant R126W or P509S mortalin variants (Figure 4d).
Although mutant A476T mortalin was able to revert the
phenotype of acute mortalin knockdown in human SH-SY5Y
cells, the chronic ex vivo model of human A476T fibroblasts
revealed an increased mitochondrial–lysosomal colocaliza-
tion compared with controls, and therefore supports a concept
of compensatory upregulation of organellar quality control.23
Finally, we investigated the effect of mortalin knockdown in
mouse embryonic fibroblasts (MEFs) from ATG5 knockout
(KO) mice that contain an inducible ATG5 cDNA under the
control of doxycycline.38 ATG5 is an essential component of
autophagy-specific conjugation systems that promote the
conjugation of LC3 to phosphatidylethanolamine at the
forming autophagosome, and hence ATG5 deficiency blocks
autophagy at early stages. In the presence of ATG5, a
significant increase in the number of GFP-LC3 puncta per cell
upon knockdown of mortalin was found (Figure 4e), corre-
sponding to our findings using the neuronal cell line SH-SY5Y
(Figures 4a–c and Supplementary Figures S3 and S4). In
contrast, in MEFs devoid of ATG5 the increase of GFP-LC3
puncta upon mortalin knockdown was completely abolished.
This indicates that mortalin controls the canonical autophagic
machinery.35
Loss of mortalin function leads to enhanced activation
of caspase 3 and apoptotic cell death. To investigate the
potential relevance of changes of mitochondrial morphology
and induction of autophagy after loss of mortalin function to
cell death, we analyzed cellular viability by measuring the
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LF Burbulla et al
7
Cell Death and Disease
activation of caspase 3 and the appearance of apoptotic
nuclei. Acute mortalin depletion was sufficient to induce
apoptotic cell death in vitro (Figure 5a).
To further challenge molecular quality control in the
mitochondria, we chemically induced intramitochondrial
stress via 17-allylamino-17-demethoxygeldanamycin (17-AAG)
treatment of cells. Previously, 17-AAG was described
as an inhibitor of the chaperone Hsp90 in cytoplasm and
mitochondria, thereby eliciting a UPR(mt) that promotes
apoptosis.39,40 Knockdown of mortalin sensitized SH-SY5Y
cells to 17-AAG treatment as quantified by the percentage of
apoptotic nuclei and the activation of caspase 3 (Figure 5b).
It is noteworthy that overexpression of wt mortalin in control
SH-SY5Y cells treated with 17-AAG apparently compensated for
the reduced Hsp90 activity and protected against subsequent
apoptosis. In addition, in human A476T-fibroblasts we
observed an increased susceptibility to 17-AAG treatment
with higher levels of apoptosis compared with control cells
(Figure 5c). To investigate the specificity of the loss of mortalin
function-mediated susceptibility toward increased mitochon-
drial proteolytic stress, we treated cells with thapsigargin
(TG), an inducer of endoplasmic reticulum (ER) stress.41
ER-stress caused apoptosis to a similar extent in both control
and mutant fibroblasts (Figure 5d).
The application of more specific genetically induced
intramitochondrial proteolytic stress by overexpression of
the truncated dOTC protein increased apoptosis in control
SH-SY5Y cells to a similar extent as the chemical treatment
(Figure 5e). Increased apoptotic nuclei but not activation of
caspase-3 by dOTC was further exacerbated in the mortalin
knockdown situation, suggesting that the apoptotic mechan-
ism promoted by mortalin-induced proteolytic stress does not
require caspase-3 and can act via alternative execution
pathways. Notably, the overexpression of native OTC in a
mortalin knockdown background induced apoptosis to a
similar extent as control cells transfected with dOTC. This
indicates that proteolytic stress due to dOTC overexpression
recapitulates the effect of mortalin knockdown in terms of
cellular viability. Knockdown of mortalin in combination with
the expression of the dOTC protein showed the most severe
effect on cell viability.
Increased organellar quality control due to overexpres-
sion of either PINK1 or Parkin rescues loss of mortalin
function phenotypes. The enhanced mitophagy observed
in response to mortalin knockdown might exacerbate defects
because of a depletion of mitochondria. Alternatively, it might
be essential to prevent further cellular damage. To address
this question, we sought to modulate autophagy in cells
affected by the loss of mortalin function.
Chemical induction of autophagy by Rapamycin reduced
apoptosis in mortalin knockdown models as revealed by
decreased caspase 3 activation and a reduced number of
apoptotic nuclei (Figure 6a), as well as a reduced Annexin V
staining revealed by FACS analysis (Supplementary Figure S5).
In line with these observations, an inhibition of autophagy by
use of the lysosomal inhibitor BafA1 in mortalin knockdown
cells exacerbated apoptosis (Figure 6b). This clearly supports
a critical role of functional autophagic machinery to prevent
further damage.
Intriguingly, the mitochondrial quality control machinery is
critically related to PD genes encoding PINK1 and Parkin as
mediators of the autophagic degradation of dysfunctional
mitochondria. Therefore, to reduce the proportion of nonfunc-
tional mitochondria among the mitochondrial pool, we
genetically upregulated mitochondrial quality control
proteins28 by overexpressing either PINK1 or Parkin in cells
treated with mortalin siRNA and monitored the resulting
phenotypes. Both PINK1 and Parkin overexpression in a
mortalin knockdown background resulted in significantly
enhanced numbers of GFP-LC3 puncta compared with the
control condition (Figure 6c). These results argue in favor of
an activation of autophagy to degrade impaired mitochondria.
Consistently, the mitochondrial fragmentation phenotype in
mortalin knockdown cells was rescued by overexpression of
either PINK1 or Parkin (Figure 6d).
To define whether our observations on positive effects of
PINK1 and Parkin on mitochondrial network homeostasis
were related to increased clearance of fragmented mitochon-
dria from the cell, we used the ATG5 KO model in MEFs. In
control MEFs expressing ATG5, PINK1 partially and Parkin
fully rescued the mitochondrial phenotype upon mortalin
knockdown, in line with our observations in human neuronal
Figure 4 Proteolytic stress causes increased mitochondrial clearance loss of mortalin function models. (a, left panel) Fluorescence microscopy in fixed cells (n¼ 252 cells)
was used to analyze the number of autophagosome by overexpressing GFP-LC3 (green) in mortalin and control siRNA-treated SH-SY5Y. Cells were transfected with wt
mortalin or mortalin variants in the ratio of 1 : 4 together with GFP-LC3 (controls for positive transfection of the mortalin plasmid). Successful siRNA transfection was confirmed
by fluorescence of the Alexa555 tag of the siRNA (red). Hoechst 33342 stained nuclei (blue). (a, right panel) Mortalin siRNA-treated cells have a higher number of GFP-LC3
puncta compared with control siRNA-treated cells. The reintroduction of wt mortalin but not the variants rescued this phenotype. Scale bar indicates 10mm. (b, left panel) Use
of the autophagy inhibitor Bafilomycin A1 (BafA1) in SH-SY5Y cells (n¼ 188) leads to enhanced numbers of GFP-LC3 puncta (green) in both control and mortalin
siRNA-treated cells (red). (b, right panel) Mortalin siRNA-treated cells have a higher number of GFP-LC3 puncta compared with control siRNA-treated cells. Treatment with
BafA1 resulted in a further increase of GFP-LC3 puncta in the mortalin knockdown as well as control condition. Scale bar indicates 10 mm. (c) SH-SY5Y cells expressing
mortalin miRNA or control miRNA for 24, 48 or 72 h were treated with EBSS and Bafilomycin A1 (BafA1) followed by anti-WIPI-2 immunoflourescence. Confocal fluorescence
microscopy (Zeiss LSM 510) image projections (n¼ 10) were used (representative images in the left panels) to assess the number of endogenous WIPI-2 puncta per cell using
ImageJ software analysis (right panels). Knockdown of mortalin (black bars) significantly increased the number of WIPI-2 puncta per cell (or the total fluorescent area;
Supplementary Figure S3) when compared with control cells (gray bars). Scale bar indicates 20mm. (d) Fluorescence microscopy in fixed cells (n¼ 244 cells) was used to
analyze mitochondrial–lysosomal colocalization in mortalin and control siRNA-treated SH-SY5Y with or without overexpressed wt mortalin or mortalin variants. Successful
siRNA transfection was confirmed by fluorescence of the Alexa555 tag of the siRNA (red). Mitochondria were visualized by Tom20 antibody (far red), lysosomes by Lamp-1
(green) and Hoechst 33342-stained nuclei (blue). Mortalin siRNA-treated cells revealed a higher value for the Pearson coefficient as a measure for colocalization rate.
The reintroduction of wt mortalin but not the R162W or P509S mortalin variants rescued this phenotype. A476T mortalin showed no significant difference to the wt mortalin
condition. Ctrl, control; EV, empty vector. Scale bar indicates 10mm. (e) Knockdown of mortalin in ATG5 WT MEFs along with transient expression of GFP-LC3 resulted in an
increased number of autophagosomes (GFP-LC3 puncta) compared with control siRNA-treated ATG5 WT MEFs (n¼ 72 cells). In ATG5 KO MEFs (n¼ 82 cells), transient
expression of GFP-LC3 did not result in an increased puncta formation, because the formation of autophagosomes was abolished. It is noteworthy that the absolute number of
GFP-LC3 puncta may differ between mortalin knockdown in human versus murine cells, as expected.33 Ctrl, control
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SH-SY5Y cells (Figure 7a). In contrast, neither PINK1 nor
Parkin overexpression rescued the mitochondrial fragmenta-
tion in ATG5 KO MEFs (Figure 7b). The wt mortalin
overexpression resulted in a healthy mitochondrial network
in both ATG5 WT and KO MEFs. This may indicate that the
mechanism of rescue by overexpression of wt mortalin is not
dependent on autophagosome formation (organellar quality
control), but may reduce the intramitochondrial proteolytic
disturbances resulting from mortalin knockdown. Whereas the
rescue by wt mortalin overexpression acts within the
mitochondria, an overexpression of either PINK1 or Parkin
acts at the autophagy stage and cannot be successful in cells
devoid of autophagosomes.
To define whether an increased mitochondrial clearance
in mortalin knockdown cells may be beneficial or rather toxic
for the cells, we measured apoptotic cell death by Annexin V
analysis. We found reduced levels of apoptosis under
conditions of induced autophagy after overexpression of
Parkin in mortalin knockdown cells (Figure 7c). This argues for
a role of Parkin in rescuing the loss of mortalin by induction of
Figure 4 (Continued)
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autophagy in mortalin siRNA-treated cells (Figure 7c). PINK1
overexpression showed an effect on cell survival, but was not
statistically significant. Finally, we investigated the link
between mortalin loss of function and Parkin-mediated
mitophagy by assessing the effect of expressing myc-Parkin
in our mortalin knockdown paradigm. Therefore, we assessed
an early stage of Parkin-mediated mitophagy that is defined
by clustering of mitochondria and that precedes mitochondrial
Figure 4 (Continued)
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removal.42 We knocked down mortalin using an inducible
miRNA system in HeLa cells, which are devoid of endogenous
Parkin,42 and introduced recombinant myc-Parkin in mortalin
knockdown as well as control cells. In accordance with our
previous finding in SH-SY5Y cells and patient fibroblasts, the
mitochondria in HeLa cells were fragmented when mortalin is
knocked down. However, a significant increase in mitochon-
drial clustering as a readout for the induction of mitophagy
was only observed after the introduction of Parkin in
mortalin knockdown cells (Figure 7d). These sequestered
Figure 5 (Continued)
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Figure 5 Impaired mitochondrial proteostasis leads to increased apoptosis in human cells with reduced mortalin levels and is rescued by induction of the autophagic
pathway (a, left panel) Fluorescence microscopy in fixed cells (n¼ 272 cells) was used to analyze the number of apoptotic nuclei by Hoechst staining (blue) and a positive
signal for activated caspase 3 (far red). Cells were transfected with wt mortalin or empty vector in the ratio of 1 : 4 together with an empty eGFP-N1 vector (controls for positive
transfection of the mortalin plasmid). Successful siRNA transfection was confirmed by fluorescence of the Alexa555 tag of the siRNA (red). (a, right panel) Mortalin siRNA-
treated cells have a higher number of apoptotic nuclei and cells with activated caspases 3. The reintroduction of wt mortalin rescued this apoptotic cell death phenotype. Ctrl,
control; EV, empty vector. Scale bar indicates 10 mm. (b) The pharmacological compound 17-AAG was used for induction of intramitochondrial proteolytic stress in fixed SH-
SY5Y cells. Cells were transfected with wt mortalin or empty vector in the ratio of 1 : 4 together with an empty eGFP-N1 vector (controls for positive transfection of the mortalin
plasmid). Successful siRNA transfection was confirmed by fluorescence of the Alexa555 tag of the siRNA (red). Treatment with 17-AAG in mortalin siRNA-treated cells leads to
enhanced numbers of apoptotic nuclei (blue) and activation of caspase 3 (far red). Overexpression of wt mortalin fully reversed the phenotype in both control and mortalin
knockdown cells. Scale bar indicates 10 mm. (c) Fluorescence microscopy in fixed human fibroblasts (n¼ 206) revealed enhanced apoptosis in terms of an increase in
apoptotic nuclei (blue) and in caspase 3 activation (green) in cells from a carrier of the A476T mortalin variant compared with control fibroblasts upon induction of
intramitochondrial proteolytic stress via 17-AAG treatment. Scale bar indicates 10 mm. (d) Induced specific ER stress by treatment with thapsigargin (TG) causes apoptosis to
a similar extent in control as well as in fibroblasts from a carrier of the A476T mortalin variant (n¼ 336). Induction of ER stress increased the amount of apoptotic nuclei as well
as caspase-3 activation in control and mutant fibroblast to the same amount (435%), underscoring the specificity of intramitochondrial stress due to loss of mortalin function.
(e) Expression of the dOTC protein leads, in both control and mortalin knockdown SH-SY5Y cells (n¼ 428), to an increase in apoptotic nuclei as well as in caspase 3 activation
compared with the respective counterparts with expression of the OTC protein. Transfection of the OTC protein in mortalin siRNA-treated cells caused similar amount of
apoptosis compared with the condition of dOTC expression in control cells. The increase in apoptotic nuclei but not in the activation of caspase-3 upon expression of dOTC in
the mortalin knockdown situation suggests that the apoptotic mechanism promoted by mortalin-induced proteolytic stress does not require caspase-3 and can act via
alternative execution pathways
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mitochondria were previously described in paradigms of
carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-induced
mitophagy.42,43 In sum, the functional quality control system,
enhanced by the overexpression of PINK1 or Parkin, lead to
the activation of autophagy and in consequence to a rescue of
the mitochondrial network in mortalin knockdown cells,
thereby explaining the ability of Parkin to rescue mortalin
knockdown cells from apoptosis.
Discussion
The genetic basis for disrupted mitochondrial integrity as a
cause of neurodegeneration in PD was uncovered by the
functional characterization of mutations that cause loss of
Parkin or PINK1 function in autosomal recessive forms of the
disease. A linear signaling pathway, with PINK1 acting
upstream of Parkin, was described.24,25 This pathway controls
the proper clearance of dysfunctional mitochondria from the
cell.25 In this context, PINK1 is stabilized on the outer
membrane of defective mitochondria and activates the process
that leads to the recruitment of the E3 ubiquitin ligase Parkin to
the dysfunctional organelle, finally leading to lysosomal
degradation.44 Recently, the PINK1-mediated phosphorylation
of mitofusin 2 (Mfn2) was found to be the critical step for the
initiation of mitophagy via ubiquitination of Mfn2, with phospho-
rylated Mfn2 acting as a receptor for Parkin.45
Figure 6 Rapamycin treatment or overexpression of PINK1 or Parkin rescues cellular phenotypes associated with loss of mortalin function (a) Cells were treated with
control siRNA or mortalin siRNA and analyzed for apoptotic nuclei and activation of caspase 3 via immunofluorescence studies. The induction of autophagy by treatment with
Rapamycin resulted in a significantly lower amount of caspase 3 activation as well as apoptotic nuclei in the mortalin knockdown condition compared with the control condition.
(b) Cells were treated with control siRNA or mortalin siRNA and analyzed for apoptotic cell death via Annexin V staining measured by FACS analysis. Knockdown of mortalin
resulted in an increased Annexin V signal. The inhibition of lysosomal function by treatment with BafA1 enhanced the Annexin V signal in both control and mortalin knockdown
condition. (c) Fluorescence microscopy in fixed cells (n¼ 197 cells) was used to analyze the number of autophagosome by overexpressing GFP-LC3 (green) in mortalin and
control siRNA-treated SH-SY5Y. Cells were transfected with wt mortalin, PINK1 or Parkin in the ratio of 1 : 4 together with GFP-LC3 (controls for positive transfection of the
mortalin plasmid). Mortalin siRNA-treated cells have a higher number of GFP-LC3 puncta compared with control siRNA-treated cells. The overexpression of wt mortalin
resulted in a decreased number of GFP-LC3 puncta, whereas the overexpression of PINK1 or Parkin was followed by an enhanced number of GFP-LC3 puncta compared with
the control condition. (d) Fluorescence microscopy in fixed cells (n¼ 214 cells) was used to analyze mitochondrial morphology in mortalin and control siRNA-treated SH-SY5Y
with or without overexpressed wt mortalin, PINK1 or Parkin. Mortalin siRNA-treated cells have a smaller mitochondrial form factor, aspect ratio and mitochondrial size (area per
mitochondrion). The reintroduction of either wt mortalin, PINK1 or Parkin rescued this mitochondrial fragmentation phenotype
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Our results now provide evidence for an involvement of
impaired intramitochondrial molecular quality control in PD
mediated by loss of mortalin function. Importantly, mitochon-
drial dysfunction and altered integrity were compensated by
PINK1/Parkin-mediated autophagy, representing down-
stream organellar quality control. We found that loss of
mortalin causes intramitochondrial proteolytic stress in vitro
and ex vivo as defined by increased expression level of
Hsp60, a marker for the activation of the UPR(mt).29
Activation of the UPR(mt) was further supported by the
observed mitonuclear protein imbalance and an accumulation
of insoluble proteins within the mitochondria. Consistently,
human neuronal cell lines with reduced levels of mortalin were
more vulnerable to chemically or genetically induced intrami-
tochondrial proteolytic stress, an effect that was also
observed in fibroblasts from a carrier of the A476T variant
Figure 7 Rescue of mitochondrial fragmentation phenotype due to mortalin knockdown by Parkin overexpression requires an intact autophagic machinery leading to
reduced cell death. (a) Fluorescence microscopy in fixed cells (n¼ 94 cells) was used to analyze mitochondrial morphology in mortalin and control siRNA-treated MEFs with or
without overexpressed wt mortalin, PINK1 or Parkin. Mortalin siRNA-treated cells have a smaller mitochondrial form factor, aspect ratio and mitochondrial size (area per
mitochondrion). The reintroduction of either wt mortalin or Parkin rescued this mitochondrial fragmentation phenotype. Reintroduction of PINK1 resulted only partially in the
rescue of mitochondrial fragmentation. This suggests that successful rescue through Parkin overexpression is dependent on ATG5 (compare also Figure 7b), whereas PINK1
does not appear to be affected by ATG5. (b) Fluorescence microscopy in fixed cells (n¼ 102 cells) was used to analyze mitochondrial morphology in mortalin and control
siRNA-treated ATG5 KO MEFs with or without overexpressed wt mortalin, PINK1 or Parkin. Mortalin siRNA-treated cells have a smaller mitochondrial form factor, aspect ratio
and mitochondrial size (area per mitochondrion). Only the reintroduction of wt mortalin rescued this mitochondrial fragmentation phenotype, whereas neither overexpression of
PINK1 nor of Parkin did. (c) SH-SY5Y cells were treated with control siRNA or mortalin siRNA and analyzed for apoptotic cell death via Annexin V staining measured by FACS
analysis. Knockdown of mortalin resulted in an increased Annexin V signal. Overexpression of wt mortalin or Parkin in cells treated with mortalin siRNA led to a full rescue of
this phenotype. PINK1 overexpression lowered the amount of Annexin V staining, but did not significantly rescue the observed phenotype in mortalin knockdown cells.
(d) Knockdown of mortalin in HeLa cells was achieved by inducible miRNA system. Myc-Parkin was transiently transfected. The clustering of mitochondria was assessed by
counting the number of mitochondrial particles per cell in those with a positive signal for miRNA only or for miRNAþmyc-Parkin in knockdown mortalin cells as well as control
cells. Knockdown of mortalin resulted in fragmentation of the mitochondrial network, whereas the exogenous introduction of myc-Parkin led to mitochondrial clustering around
the nuclear region. Cells overexpressing myc-Parkin are encircled in red. Cells overexpressing without exogenous expression of myc-Parkin are encircled in yellow
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and that was completely rescued by reintroduction of wt
mortalin. In contrast, no rescue capacity for mortalin was
observed for pharmacologically induced ER-stress in this
model, indicating the specificity of mortalin for UPR(mt) and
the importance of mortalin for the maintenance of proteostasis
within the mitochondrial matrix. Thus, we propose a linear
signaling cascade in which loss of mortalin triggers impaired
mitochondrial proteostasis that is upstream of PD-related
neurodegeneration (Figure 8).
In our experiments in different in vitro and ex vivo models of
loss of mortalin function, we found evidence for increased
autophagy due to accumulating mitochondrial damage based
on intramitochondrial proteolytic stress. We demonstrate that
the accumulation of autophagosomes upon loss of mortalin is
because of activated autophagy. Although the correlation
between the effect on autophagic activation and mitochondrial
clearance is difficult to assess, the consistent reduction of
mitochondrial mass in different loss of mortalin function
models suggests that the increase in mitochondrial clearance
is effective and represents an initial compensatory mechanism
to maintain organellar quality.
Previously identified genetic defects in Parkin and PINK1
contribute to PD pathogenesis based on their role in
mitochondrial clearance via autophagy and implicated
impaired organellar quality control.46 This, however, was
typically seen in response to toxic insults (i.e., via CCCP) that
interfere with mitochondrial homeostasis in vitro, so that the
pathophysiological relevance of these observations in neu-
rons in vivo still remains to be determined.42,47 We found that
PD-associated loss of mortalin function caused a primary
defect in intramitochondrial molecular quality control that
causes characteristic changes in mitochondrial function and
dynamics, leading to an increased autophagic activity with
increased Parkin-mediated clustering of mitochondria. These
mitochondria were subsequently cleared from the healthy
mitochondrial pool, leading to reduced mitochondrial mass in
different cellular in vitro and ex vivo models. No alterations in
cell viability under basal conditions were observed in
fibroblasts of the human carrier of the A476T mutation that
serves as a model of chronic mortalin haploinsufficiency.
However, A476T fibroblasts showed an increased suscept-
ibility toward proteolytic perturbation, indicating compensa-
tory mechanisms active over lifetime. Thus, we speculate that
the chronic impairment of the organellar quality control
machinery sensitizes cells toward apoptotic cell death
(Figure 8).
Indeed, overexpression of Parkin and PINK1 in mortalin
knockdown models was able to revert mitochondrial
Figure 8 Overview of the consequences of loss of mortalin function in human cells. A schematic view highlights the consequences of loss of mortalin function found in
different in vitro and in vivo models. Under physiological conditions, the mitochondrial chaperone mortalin is located within the mitochondrial matrix where it represents the only
ATPase component of the import machinery and is responsible for the maintenance of mitochondrial function. It fulfils an active role in the effective import as well as the proper
folding of nuclear encoded matrix proteins with the support of co-chaperones. Furthermore, mortalin occupies refolding capacity to deal with aggregated or misfolded proteins
and acts as part of the mitochondrial quality control system for aged or impaired matrix proteins. Loss of mortalin function does not have a negative effect on effective import of
mortalin into mitochondria or the interaction with other essential substrates. Hence, we consider the loss of protein function rather results in an impairment of the refolding or
degradation capacity of mortalin. Consequently, instead of passing through the refolding process, aggregated/misfolded proteins remain defective. Similarly, aged/impaired
proteins do not undergo the degradation process, but rather accumulate within the mitochondrial matrix. These alterations lead to increased ROS levels and impaired MMP,
followed by changes in mitochondrial morphology. This is turn causes a shift in the normally well-balanced system of mitochondrial dynamics toward increased fission events.
Both in vitro and in vivo, the loss of mortalin function correlates with a disequilibrium toward mitochondrial fission that either leads to lysosomal degradation of impaired
mitochondria to maintain cellular integrity or may directly guide cell death. An inhibition of autophagy by use of the lysosomal inhibitor BafA1 (red arrow) in cells with reduced
levels of mortalin exacerbates apoptosis, whereas either a genetic (PINK1 and Parkin overexpression) or pharmacological intervention (Rapamycin) enhances mitophagy so
that dysfunctional mitochondria are removed from the mitochondrial pool (green arrow). Our results in different in vitro and ex vivo models support these effects upon loss of
mortalin function either because of reduced levels of native mortalin protein or because of loss-of-function mutations in the mortalin gene
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phenotypes and reduce the susceptibility toward apoptotic cell
death. This protective effect of PINK1 and Parkin was
dependent on an intact autophagic machinery, as it was absent
in fibroblasts from ATG5 KO mice that lack ATG5 as an
essential factor for autophagosome formation.38 Similar
protective effects on cells with reduced levels of mortalin were
observed upon treatment with rapamycin, a compound known
to induce autophagy by targeting mTORC1.48 Therefore, our
results suggest that effective removal of dysfunctional mito-
chondria via genetic (PINK1 and Parkin overexpression) or
pharmacological intervention (rapamycin) may compensate
mitochondrial phenotypes due to loss of mortalin.
The loss-of-function mechanism of PD-associated mortalin
variants was suggested by an incomplete rescue of loss of
mortalin-associated mitochondrial phenotypes by mutant
R126W, A476T and P509S mortalin11 compared with wt
mortalin in vitro. Furthermore, characteristic mitochondrial
alterations in fibroblasts from the carrier of the A476T variant
were observed ex vivo. Interestingly, a recent in vitro study in
yeast also supported a loss of chaperone function for the
PD-associated mortalin variants R126W and P509S using
biochemical assays with purified recombinant proteins and a
functional complementation assays in yeast.49 We also
performed experiments to rescue the inviable yeast mtHsp70
(Ssc1)-null strain with either native Ssc1 or Ssc1 carrying the
analogous PD-associated variants (R103W Ssc1 8 human
R126W mortalin; P486S Ssc1 8 human P509S mortalin). We
confirmed a severe growth defect for cells harboring the
ATPase domain mutant R103W Ssc1 and consistently found
no significant difference for cells complemented with P486S
compared with native Ssc1 (see Supplementary Figure S6
and Goswami et al.49). Using A453T Ssc1 that corresponds to
the A476T variant found in German PD patients,11 we found
similar effects on growth as for the A486S Ssc1 variant, also
located in the substrate-binding domain (see Supplementary
Figure S6 and Goswami et al.49). Our findings support the
notion of differential effects of mtHsp70 variants located in the
ATPase domain or in the substrate-binding domain in yeast.
Moreover, our results in human cellular in vitro and ex vivo
models clearly show that the substrate-binding domain
variants A476T and P509S exhibit a loss of mortalin function
that translates into a phenotype of impaired mitochondrial
proteostasis and changes in mitochondrial dynamics in
human cells. These results underscore a concept of rare
heterozygous variants in the essential mortalin gene that
mediate neurodegeneration in PD via haploinsufficiency and
are in line with the recent concepts on ‘rare variants common
disease’ that were deduced from genomic approaches on
neurological diseases and support the presence of rare
variants with reduced penetrance contributing as risk factors
to common disease (reviewed in Sharma et al.50). Recently,
two novel missense variants (p.T333K and p.L358P) in the
mortalin gene have been described that challenged the
concept of mortalin variants in PD. For these variants, no
alterations in different functional assays based on over-
expression in SH-SY5Y cells were found.51 These results
underscore that mortalin variants are not a frequent cause of
PD and that functional consequences have to be carefully
explored for all variants. Our results indicate that mortalin
knockdown models in vitro or patient-based material ex vivo
are useful to determine whether novel variants may be related
to loss of mortalin function.
Based on the PD-associated symptoms of mortalin knock-
down in Drosophila melanogaster in vivo,23 together with the
concept of haploinsufficiency for disease-associated human
variants in vitro, we suggest that an age-related decline of
chaperoning capacities and subsequent collapse of protein
homeostasis (reviewed in Baker et al.52) may be responsible
for neurodegeneration and would be in line with aging as the
most important risk factor for PD.53
Any mutation or insult lowering mitochondrial quality control
capacity is predicted to preferentially affect neurons because of
their increased requirement for energy and increased risk for
accumulating mitochondrial damage. It is known that mito-
chondria in neurons exhibit a higher organellar half-life
compared with other postmitotical tissues.54,55 One reason
for the particular susceptibility of dopaminergic neurons toward
loss of mortalin function may be because of a reduced
mitochondrial mass of DA neurons in the substantia nigra
compared with other neuronal populations as has been shown
in mice.56 Translated into the human situation, the limited
equipment of DA neurons in terms of mitochondria could argue
in favor of an increased vulnerability of the cellular energy
supply toward impaired mitochondrial homeostasis, a hypo-
thesis that is supported by increasing evidence for an
involvement of the PINK1/Parkin-mediated organellar quality
control in PD.43,57 Moreover, neurons of the substantia nigra
per se apparently exhibit a reduced mitophagic capacity that, in
addition, may contribute to the selective vulnerability of DA
neurons in PD.58 We have shown in this work that (1) a loss of
mortalin function is sufficient to induce intramitochondrial
proteolytic stress, (2) the autophagic machinery is activated
in conditions of loss of mortalin function and (3) Parkin directly
enhances the clustering of mitochondria in cells with reduced
mortalin levels (Figure 7d). Parkin is part of an important step of
the autophagic clearance machinery of damaged mitochondria
from the cell. Therefore, overexpression of Parkin in human
and murine models of loss of mortalin function may help to
more efficiently remove dysfunctional mitochondria. This would
further revert the altered mitochondrial morphology and protect
from cell death (Figure 6d and Figures 7a–c). Indeed, rescue
experiments including both PINK1 and Parkin point to a
protective role of the PINK1/Parkin pathway being essential
for removal of dysfunctional mitochondria as a result of mortalin
loss of function.
In summary, our study emphasizes the importance of
mortalin for mitochondrial proteostasis and underscores the
relevance of impaired protein quality control within the
mitochondria in initiating a cascade of events leading to cell
death. Our findings further stage mortalin-mediated disruption
of mitochondrial integrity into the context of Parkin- and
PINK1-associated PD phenotypes.
Materials and Methods
Cloning of wt and mutant mortalin. Cloning of mortalin cDNA and its
mutagenesis for insertion of the R126W, A476T and P509S variants has been
described previously.11
Cell culture, transfection and generation of stable cell lines. Skin
biopsies were taken from one offspring of a PD patient, both carrying the
heterozygous A476T variant in the mortalin gene, and an unaffected sibling
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control. The carrier of the A476T variant did not show signs of PD at that time. All
biopsies were obtained with patient’s consent and approval of the local ethics
committee.
Cell culture of SH-SY5Y and HEK293 cells and human fibroblasts has been
described previously.11 The m5-7 MEFs were prepared to achieve a knockout of
ATG5 as previously described.37 Passage number of fibroblasts was o10 for all
experiments. Only fibroblasts with the same passage number were taken.
Western blot. Cell lysis was carried out identically for SH-SY5Y cells, HEK293
cells and human fibroblasts as well as MEFs. Cells were washed with phosphate-
buffered saline (PBS) and detached with Trypsin at 371C for 3 min. After 5 min of
centrifugation at 14 000 r.p.m., cells were lysed in buffer containing 0.1% Triton
X-100 in PBS and 1 protease inhibitor cocktail (Roche, Penzberg, Germany).
Proteins were detected by using antibodies against mortalin (anti-GRP75,
Santa Cruz Biotechnology, Dallas, TX, USA), b-Actin (Sigma-Aldrich, Munich,
Germany), GAPDH (Life Technologies, Carlsbad, CA, USA), Tom20 (Santa Cruz
Biotechnology), Hsp60 (from A Azem, Tel-Aviv University, Ramat Aviv, Israel),
activated caspase 3 (Cell Signaling Technology, Danvers, MA, USA), activated
caspase 9 (Cell Signaling Technology), Flag (Sigma-Aldrich), a-tubulin
(Sigma-Aldrich), b-Tubulin (anti-b-Tubulin, (E7), Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, IA, USA), GAPDH (anti-GAPDH
(G9545), Sigma-Aldrich) and rodent OXPHOS (no. MS604 Mitoscience (Abcam),
Cambridgeshire, UK). Secondary antibodies were purchased from GE Healthcare
(Buckinghamshire, UK).
Densitometry from western blot was performed using the ImageJ 1.41o software
(Wayne Rasband; National Institutes of Health, Bethesda, MD, USA).
Preparation of mitochondrial fractions. Mitochondria were purified
from tetracycline-induced (nontargeting or mortalin miRNA) knockdown SH-SY5Y
cells in homogenization buffer containing 10 mM HEPES (pH 7.4), 50 mM sucrose,
0.4 M mannitol, 10 mM KCL and 1 mM EGTA, using a two-step differential
centrifugation at 600 g and 3000 g, respectively, for 15 min at 41C. The
mitochondria-enriched fraction was resuspended in a buffer containing 20 mM
HEPES (pH 7.4), 0.4 M mannitol, 10 mM NaH2PO4 and 0.5 mM EGTA to equal
protein concentration of 1mg/ml. Equal amounts of this mitochondrial fraction were
added to equal volumes of a lysis buffer containing 4% (w/v) SDS or 2% (v/v)
NP40. Proteins were resolved in NuPAGE 4–12% gradient gels (Life
Technologies) and visualized by silver staining or for western blot analysis using
the indicated antibodies as described in Moisoi et al.59
Silver stain of soluble and insoluble mitochondrial fractions.
NuPAGE gradient gels were first placed in 10% (v/v) ethanol for 10 min on a
shaker and then in 1% (v/v) HNO3 (Roth, Karlsruhe, Germany) for 15 min before
incubation with 0.2% (w/v) AgNO3 (Sigma-Aldrich) for 30 min. After a short wash
with ddH2O, bands were made visible with 3% (w/v) Na2CO3 (Roth) with 50ml
formaldehyde solution (Sigma-Aldrich) per 100 ml. The reaction was stopped with
10% (v/v) acetic acid (Merck, Darmstadt, Germany) for 2 min when the staining
was sufficient and gels were kept in ddH2O until digitalization.
Mitonuclear imbalance. The mitochondrial SDS fraction of equalized
lysates (described above) were resolved on NuPAGE 4–12% gradient gels (Life
Technologies) and western blots probed for total rodent OXPHOS (AbCam
110413, MS604) that contains antibodies against ATP5A (nuclear encoded) and
MTCO1 (mitochondrially encoded) according to Houtkooper et al.26 Tom20 was
used as an additional loading control (Santa Cruz Biotechnology). A representative
western blot is shown. Densitometry of each band from three independent
experiments was calculated using ImageJ and the mitonuclear imbalance
expressed as a ratio of proteins expressed from nuclear DNA to mitochondrial
DNA according to Houtkooper et al.26
RNA interference-mediated downregulation of mortalin and
overexpression of DNA plasmids. Mortalin knockdown was achieved
by transfection of Flexitube siRNA (Hs_HSPA9_1, 30-AlexaFluor555) or chemically
unmodified nontargeting control siRNA (AllStars Negative siRNA AF 555) from
Qiagen (Hilden, Germany) into SH-SY5Y cells. A total of 70 000 cells were
transfected with 160 nM of siRNA or negative control siRNA using HiPerFect
transfection reagent (Qiagen), leading to a reduction in mortalin protein of 470%
in cells transfected with mortalin siRNA compared with control cells
(Supplementary Figure S1A).
For mortalin knockdown using a tetracycline-inducible miRNA system (BLOCK IT,
Life Technologies), miRNA sequences were designed targeting two regions on the
mortalin gene (nucleotide start sites 773 and 1939) that were chained together and
under polycistronic control of the same promoter in the same pcDNA 6.2-GW/
EmGFP-miR miRNA vector backbone. Induced expression was monitored by EmGFP
fluorescence (EmGFP-miR vector, Life Technologies) and by western blot. Additional
transfection of any plasmid was achieved using HiPerFect transfection reagent.
Immunofluorescence microscopy upon transient transfection
of siRNAs. For immunocytochemistry, cells were seeded on collagen-coated
slides. For successful knockdown of mortalin, siRNA was transfected 5 h after
seeding the cells. GFP-LC3 and respective plasmids were transfected in the ratio
of 1 : 4 using HiPerFect transfection reagent 12 h after siRNA treatment to control
for positive transfection. Cells positive for GFP-LC3 were considered as also
harboring the other plasmid. Analysis of the number of GFP-LC3 puncta per cell
was done via an unbiased automatical counting approach using ImageJ software.
For colocalization and morphology studies, reintroduction of any plasmid was
similarly applied 12 h after siRNA treatment. For OTC/dOTC experiments, the
plasmid was transfected 5 h after seeding the cells. In this condition, siRNA was
applied 12 h after plasmid transfection. If needed for rescue experiments, wt
mortalin or empty vector were cotransfected with empty pEGFP-N1 plasmid in the
ratio of 1 : 4 to control for successful plasmid transfection. Fixation of cells occurred
24 h after the transfection procedure.
To chemically elicit a mitochondrial unfolded stress response, cells were treated
with 0.25mM of the Hsp90 inhibitor 17-AAG for 30 h before fixation. To induce ER
stress leading to Ca2þ depletion, cells were treated with 30mM for 5 h. Lysosomal
inhibition was evoked by treatment with 100 nM BafA1 for 1 h followed by incubation
in normal medium for 4 h. BafA1 prevents the fusion between autophagosomes and
lysosomes and is an established method to assess the autophagic flux. For
activation of autophagy, cells were incubated with 100 nM Rapamycin for 24 h.
Fixation procedure and microscopic analysis were performed as described
previously.11 If needed, cells were incubated for 15 min in 100 nM Lyostracker Red
DND-99 (Life Technologies) before fixation. Proteins were detected by using
antibodies against mortalin (anti-GRP75, Santa Cruz Biotechnology), Tom20 (Santa
Cruz Biotechnology), Lamp-1 (Hybridoma Bank of Iowa University), cleaved
Caspase-3 (Cell Signaling Technology) and Flag (Sigma-Aldrich). Secondary
antibodies were purchased from Life Technologies or Zymed (San Francisco, CA,
USA). Hoechst 33342 (Life Technologies) was used to stain nuclei.
Images were analyzed by Zeiss software AxioVision 4.6 (Zeiss, Jena, Germany)
and ImageJ 1.41o software.
Immunofluorescence microscopy analysis of endogenous
WIPI-2 puncta formation and endogenous p62 localization. To
assess endogenous WIPI-2 puncta formation, SH-SY5Y cells with inducible
expression of miRNA targeting mortalin were seeded on coverslips in 24-well plates
(50 000 cells per well). Mortalin miRNA expression was induced for 24, 48 and 72 h
using 1mg/ml tetracycline, followed by a 3-h incubation in starvation medium (Earle’s
balanced salt solution (EBSS)) including BafA1 (200 nM). Subsequently, cells were
fixed in 4% paraformaldehyde and indirect immunofluorescence conducted as
previously described34 using anti-WIPI2 antibodies (1 : 50, Abgent, San Diego,
CA, USA) and anti-IgG-Alexa546 (1 : 200, Life Technologies). Using confocal
microscopy (Zeiss LSM 510) and ImageJ analysis, the number of WIPI-2 puncta per
cell as well as fluorescent puncta area was determined.
To assess endogenous p62 localization, SH-SY5Y cells with inducible
expression of miRNA targeting mortalin were seeded in 96-well plates (10 000
cells per well) and grown in tetracycline-containing medium for 72 h followed by a
3-h treatment with control medium (CM) or EBSS in the presence or absence
of BafA1 include concentration of BafA (200nM). Cells were fixed in 4%
paraformaldehyde and indirect immunofluorescence conducted as previously
described34 using anti-p62 antibodies (1 : 50, Santa Cruz, Dallas, TX, USA) and
anti-IgG-Alexa546 (1 : 200, Life Technologies) and DAPI to stain cell nuclei. Using
an automated image acquisition and analysis platform, p62 inclusions (puncta) per
cell were imaged and analyzed from up to 5000 cells as previously described.37
Parkin recruitment studies. CCCP and Valinomycin are the only known
inducers of Parkin-mediated mitophagy,42,43 yet there is a lack of accepted
methods to assess Parkin translocation following induction with other toxins such
as rotenone. Therefore, we assessed the intermediate clustering of mitochondria
preceding mitochondrial removal.42 We knocked down mortalin using an inducible
miRNA system in HeLa cells that are devoid of endogenous Parkin.42 Exogenous
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myc-Parkin was introduced and the mitochondria in cells positive for miRNA only
or miRNAþmyc-Parkin were analyzed for number per cell using ImageJ
(threshold 18-infinity and number of mitochondrial particles).
Live cell imaging microscopy. Live cell imaging was assessed to study
mitochondrial morphology and mass as well as colocalization of mitochondria
with lysosomes. Cells were cultured in Lab-TekHII chambered coverglasses
(155382; NalgeNunc International, Penfield, NY, USA).
For mitochondrial morphology and mass as well as colocalization studies,
mitochondria were visualized by 100 nM MitoTracker Green FM (Life Technologies),
lysosomes by 100 nM Lyostracker Red DND-99 (Life Technologies) and nuclei by
Hoechst 33342 after an incubation time of 15 min. In studies using Lyostracker Red
DND-99, the dye was also present within the medium during imaging the cells for
improved visualization of lysosomes. Live cell imaging analysis was performed as
described previously.11 The series of images were saved uncompressed and
analyzed with AxioVision software (Zeiss) and ImageJ 1.41o software, respectively.
Analysis of morphology and mass of mitochondria. Analysis of
mitochondrial morphology was done as described previously. Morphological
characteristics such as form factor, aspect ratio, area circularity and mitochondrial
mass were evaluated using ImageJ software. To analyze the mitochondrial mass,
the total area of mitochondria per single cell was calculated.
Fluorescence-activated cell sorting. Briefly, SH-SY5Y cells were
washed with PBS at room temperature and then incubated in either Annexin V
binding buffer (Biolegend, San Diego, CA, USA) or the same buffer containing
Annexin V-Pacific blue (BioLegend, according to the manufacturer’s titration) for
15 min on ice. Cells were sorted on a CyAn ADP (Beckman Coulter, Brea, CA,
USA) FACS machine according to their Annexin V-Pacific Blue signal above the
precontrolled threshold set by the unstained control cells. The percent of cells in
the population above this threshold was also gated for those cells containing
control siRNA-647 or Mortalin siRNA-647 fluorescent signal.
LC3 lipidation. To assess endogenous enogenous LC3 lipidation, SH-SY5Y
cells with inducible expression of miRNA targeting mortalin were seeded in 24-well
plates (50 000 cells per well). Mortalin miRNA expression was induced for 72 h
using 1 mg/ml tetracycline, followed by a 3-h incubation in control medium or
starvation medium (EBSS) including BafA1 (200 nM) or not. Subsequently, cells
were lysed in hot Laemmli buffer and resolved by SDS-PAGE. Using LC3
antibodies (Nanotools, Munich, Germany), unconjugated LC3 (LC3-I) and
PE-conjugated LC3 (LC3-II) were detected by standard ECL procedures and
PeqLab Fusion SL (Erlangen, Germany).
Statistical analysis. The imaging data were analyzed using Student’s t-test;
all the statistical tests were nonpaired two sided and those with a P-value of
o0.05 were considered to be statistically significant. Data are expressed as
mean±S.E. values (*Po0.05; **Po0.01; ***Po0.001).
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